Clene Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
79
- Stock Symbol
-
CLNN
- Investments
-
1
- Share Price
-
$3.74
- (As of Monday Closing)
Clene General Information
Description
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Contact Information
Website
www.clene.comCorporate Office
- 6550 South Millrock Drive
- Suite G50
- Salt Lake City, UT 84121
- United States
Corporate Office
- 6550 South Millrock Drive
- Suite G50
- Salt Lake City, UT 84121
- United States
Clene Timeline
Clene Stock Performance
As of 16-Nov-2026, Clene’s stock price is $3.74. Its current market cap is $53.9M with 14.4M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.74 | $3.97 | $3.02 - $10.84 | $53.9M | 14.4M | 107K | -$2.30 |
Clene Financials Summary
As of 30-Sep-2026, Clene has a trailing 12-month revenue of $238K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 70,666 | 74,047 | 50,608 | 27,890 |
| Revenue | 238 | 200 | 342 | 654 |
| EBITDA | (22,704) | (22,219) | (34,556) | (44,630) |
| Net Income | (26,826) | (26,173) | (39,400) | (49,504) |
| Total Assets | 22,157 | 18,131 | 27,337 | 52,341 |
| Total Debt | 22,604 | 21,673 | 20,843 | 32,161 |
Clene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Clene Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Clene Comparisons
Industry
Financing
Details
Clene Competitors (25)
One of Clene’s 25 competitors is Lisata Therapeutics, a Corporation company based in Basking Ridge, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Organogenesis Holdings | Pending Transaction (M&A) | Canton, MA | ||||
| Octane Medical Group | Corporate Backed or Acquired | Kingston, Canada | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA |
Clene Patents
Clene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2014262673-A1 | Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination | Active | 08-May-2013 | ||
| AU-2014262673-B2 | Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination | Active | 08-May-2013 | ||
| CA-2913205-A1 | Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination | Active | 08-May-2013 | ||
| CA-2913205-C | Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination | Active | 08-May-2013 | ||
| EP-2994146-A2 | Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination | Active | 08-May-2013 | A61K33/24 |
Clene Signals
Clene Acquisitions (1)
Clene’s most recent deal was a Merger/Acquisition with Tottenham Acquisition. The deal was made on 30-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tottenham Acquisition | 30-Dec-2020 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Clene ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.48 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Clene FAQs
-
When was Clene founded?
Clene was founded in 2012.
-
Where is Clene headquartered?
Clene is headquartered in Salt Lake City, UT.
-
What is the size of Clene?
Clene has 79 total employees.
-
What industry is Clene in?
Clene’s primary industry is Drug Discovery.
-
Is Clene a private or public company?
Clene is a Public company.
-
What is Clene’s stock symbol?
The ticker symbol for Clene is CLNN.
-
What is the current stock price of Clene?
As of 16-Nov-2026 the stock price of Clene is $3.74.
-
What is the current market cap of Clene?
The current market capitalization of Clene is $53.9M.
-
What is Clene’s current revenue?
The trailing twelve month revenue for Clene is $238K.
-
Who are Clene’s competitors?
Lisata Therapeutics, Denali Therapeutics, Organogenesis Holdings, Octane Medical Group, and Capricor Therapeutics are some of the 25 competitors of Clene.
-
What is Clene’s annual earnings per share (EPS)?
Clene’s EPS for 12 months was -$2.30.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process